Novartis (NVS) announced that its previously announced tender offer by Torino Merger Sub (TRML), a Delaware corporation and an indirect wholly owned subsidiary of Novartis, to acquire all of the outstanding shares of common stock, par value $0.0001 per share, of Tourmaline Bio at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding, expired at one minute following 11:59 p.m., Eastern Time, on October 27, 2025. The parties expect the transaction to close on October 28, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the offer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis price target raised to CHF 108 from CHF 105 at Morgan Stanley
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Video: Merger Monday with deals announced in biotechnology and banking
- Avidity acquisition has positive read for Dyne Therapeutics, says Morgan Stanley
- Dyne Therapeutics up 37% after Avidity gets bought